1-11 of 11
Anas Younes
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

Caitlin M. Stewart, Laure Michaud, Karissa Whiting, Reiko Nakajima, Chelsea Nichols, Stephanie De Frank, Paul A. Hamlin, Jr, Matthew J. Matasar, John F. Gerecitano, Pamela Drullinsky, Audrey Hamilton, David Straus, Steven M. Horwitz, Anita Kumar, Craig H. Moskowitz, Alison Moskowitz, Andrew D. Zelenetz, Jurgen Rademaker, Gilles Salles, Venkatraman Seshan, Heiko Schöder, Anas Younes, Dana W.Y. Tsui, Connie Lee Batlevi
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 45–56.
https://doi.org/10.1158/1078-0432.CCR-21-2183
Published: 05 January 2022
View article titled, Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Open the PDF for Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring in another window
Includes: Supplementary data
Journal Articles

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

Radhakrishnan Ramchandren, Ranjana H. Advani, Stephen M. Ansell, Nancy L. Bartlett, Robert Chen, Joseph M. Connors, Tatyana Feldman, Andres Forero-Torres, Jonathan W. Friedberg, Ajay K. Gopal, Leo I. Gordon, John Kuruvilla, Kerry J. Savage, Anas Younes, Gerald Engley, Thomas J. Manley, Keenan Fenton, David J. Straus
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1718–1726.
https://doi.org/10.1158/1078-0432.CCR-18-2435
Published: 15 March 2019
View article titled, Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma
Open the PDF for Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas

Anastasios Stathis, Alexia Iasonos, John F. Seymour, Catherine Thieblemont, Vincent Ribrag, Emanuele Zucca, Anas Younes
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (13): 2993–2998.
https://doi.org/10.1158/1078-0432.CCR-17-3021
Published: 01 July 2018
View article titled, Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas
Open the PDF for Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas in another window
Journal Articles

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

Jacob D. Soumerai, Andrew D. Zelenetz, Craig H. Moskowitz, M. Lia Palomba, Paul A. Hamlin, Jr, Ariela Noy, David J. Straus, Alison J. Moskowitz, Anas Younes, Matthew J. Matasar, Steven M. Horwitz, Carol S. Portlock, Jason A. Konner, Mrinal M. Gounder, David M. Hyman, Martin H. Voss, Matthew G. Fury, Devika Gajria, Richard D. Carvajal, Alan L. Ho, Jan H. Beumer, Brian Kiesel, Zhigang Zhang, Alice Chen, Richard F. Little, Christine Jarjies, Thu O. Dang, Fallon France, Nishant Mishra, John F. Gerecitano
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4119–4126.
https://doi.org/10.1158/1078-0432.CCR-16-3068
Published: 01 August 2017
View article titled, The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
Open the PDF for The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Abstract B18: Quantification of BTK engagement by ibrutinib in peripheral blood mononuclear cells in a phase I clinical study.

Shalini Chaturvedi, Cuc Davis, Stella Chang, Mint Sirisawad, Jan de Jong, Betty Chang, Anas Younes, Nele Fourneau, Sriram Balasubramanian, Brett Hall
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17_Supplement): B18.
https://doi.org/10.1158/1557-3265.HEMMAL14-B18
Published: 19 August 2015
View article titled, Abstract B18: Quantification of BTK engagement by ibrutinib in peripheral blood mononuclear cells in a phase I clinical study.
Journal Articles

Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma

Yasuhiro Oki, Daniela Buglio, Michelle Fanale, Luis Fayad, Amanda Copeland, Jorge Romaguera, Larry W. Kwak, Barbara Pro, Silvana de Castro Faria, Sattva Neelapu, Nathan Fowler, Fredrick Hagemeister, Jiexin Zhang, Shouhao Zhou, Lei Feng, Anas Younes
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6882–6890.
https://doi.org/10.1158/1078-0432.CCR-13-1906
Published: 16 December 2013
View article titled, Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma
Open the PDF for Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma in another window
Journal Articles

Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4

Conrad R. Cruz, Ulrike Gerdemann, Ann M. Leen, Jessica A. Shafer, Stephanie Ku, Benjamin Tzou, Terzah M. Horton, Andrea Sheehan, Amanda Copeland, Anas Younes, Cliona M. Rooney, Helen E. Heslop, Catherine M. Bollard
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (22): 7058–7066.
https://doi.org/10.1158/1078-0432.CCR-11-1873
Published: 14 November 2011
View article titled, Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4
Open the PDF for Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4 in another window
Includes: Supplementary data
Journal Articles

Brentuximab Vedotin (SGN-35)

Jessica Katz, John E. Janik, Anas Younes
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (20): 6428–6436.
https://doi.org/10.1158/1078-0432.CCR-11-0488
Published: 14 October 2011
View article titled, Brentuximab Vedotin (SGN-35)
Open the PDF for Brentuximab Vedotin (SGN-35) in another window
Journal Articles

Inhibition of Heat Shock Protein 90 Function by 17-Allylamino-17-Demethoxy-Geldanamycin in Hodgkin's Lymphoma Cells Down-Regulates Akt Kinase, Dephosphorylates Extracellular Signal–Regulated Kinase, and Induces Cell Cycle Arrest and Cell Death

Georgios V. Georgakis, Yang Li, Georgios Z. Rassidakis, Hector Martinez-Valdez, L. Jeffrey Medeiros, Anas Younes
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (2): 584–590.
https://doi.org/10.1158/1078-0432.CCR-05-1194
Published: 20 January 2006
View article titled, Inhibition of Heat Shock Protein 90 Function by 17-Allylamino-17-Demethoxy-Geldanamycin in Hodgkin's Lymphoma Cells Down-Regulates Akt Kinase, Dephosphorylates Extracellular Signal–Regulated Kinase, and Induces Cell Cycle Arrest and Cell Death
Open the PDF for Inhibition of Heat Shock Protein 90 Function by 17-Allylamino-17-Demethoxy-Geldanamycin in Hodgkin's Lymphoma Cells Down-Regulates Akt Kinase, Dephosphorylates Extracellular Signal–Regulated Kinase, and Induces Cell Cycle Arrest and Cell Death in another window
Journal Articles

Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease

Anas Younes, Barbara Pro, Michael J. Robertson, Ian W. Flinn, Jorge E. Romaguera, Fredrick Hagemeister, Nam H. Dang, Paolo Fiumara, Evelyne M. Loyer, Fernando F. Cabanillas, Peter W. McLaughlin, Maria Alma Rodriguez, Felipe Samaniego
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (16): 5432–5438.
https://doi.org/10.1158/1078-0432.CCR-04-0540
Published: 24 August 2004
View article titled, Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease
Open the PDF for Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease in another window
Journal Articles

Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK Receptors

Bei Zheng, Georgios V. Georgakis, Yang Li, Alok Bharti, David McConkey, Bharat B. Aggarwal, Anas Younes
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (9): 3207–3215.
https://doi.org/10.1158/1078-0432.CCR-03-0494
Published: 06 May 2004
View article titled, Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK Receptors
Open the PDF for Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK Receptors in another window